In 2019, WHO will ramp up work to eliminate cervical cancer worldwide by increasing coverage of the HPV vaccine, among other interventions.
New Year Resolutions: Ten health issues WHO will tackle this year
First trimester ondansetron exposure was not associated with an increased risk of overall congenital malformations or cardiac malformations after adjustment for known confounders.
First trimester ondansetron exposure was not associated with an increased risk of overall congenital malformations or cardiac malformations after adjustment for known confounders.
HIV in pregnancy
The United States Department of Health and Human Services (DHHS) recently updated its guidelines on the use of antiretroviral agents in pregnant women with HIV infection. Dolutegravir is newly listed as a preferred agent to initiate during the second and third trimester of pregnancy. However, the guidelines reiterate a conservative interim recommendation that dolutegravir not…
Omega-3 fatty acids and preterm birth (December 2018)
It has been hypothesized that maternal intake of omega-3 long-chain polyunsaturated fatty acids (n-3 PUFA) might reduce inflammation-mediated pregnancy disorders, such as spontaneous preterm birth.
The tumor necrosis factor inhibitor certolizumab pegol (CZP) is thought to be safe for use during pregnancy.
This biologic agent lacks the antibody Fc- region responsible for placental transfer of immunoglobulins.A recent analysis of the manufacturer’s pharmacovigilance database, representing the largest available cohort of exposed pregnant women (including over 300 women with rheumatic diseases and nearly 200 with Crohn disease), identified over 530 prospectively documented outcomes of maternal exposure. Over 80 percent…
Th Impassion Trial Data for TNBC – Breast Cancer is out!
1. This randomized controlled trial of women with metastatic triple-negative breast cancer reports that patients who were received atezolizumab with nab-paclitaxel had longer periods of progression-free survival compared to patients who received placebo plus nab-paclitaxel therapy.
FIGO introduces changes to the cervical cancer staging system (November 2018)
The International Federation of Gynecology and Obstetrics (FIGO) has published an updated cervical cancer staging system. Among the changes, the list of tests and procedures that may be used to assign stage was expanded to include imaging and pathologic findings where available, tumor size criteria for some stages were revised, and lymph node metastases were…
Targeted Drug Plus Hormone Therapy Stops Tumor Growth In Patients With Early Breast Cancer
A new clinical trial conducted in patients in the U.S., U.K., and Canada has shown that the addition of a targeted therapy drug to existing hormone treatment, greatly slows cancer cell growth in women with early-stage breast cancer.
